Ignite Creation Date:
2024-05-06 @ 3:52 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04782115
Status:
COMPLETED
Last Update Posted:
2023-12-18
First Post:
2021-03-01
Brief Title:
Evaluation of RC28-E Injection in Diabetic Macular Edema
Sponsor:
RemeGen Co Ltd
Organization:
RemeGen Co Ltd
Study Overview
Official Title:
Protein by Dual Blockage of VEGF and FGF-2 in Subjects With Diabetic Macular Edema
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a non-randomized open-label multicenter 48-week study to investigate the efficacy safety and pharmacokinetics of RC28-E injection in the treatment of patients with diabetic macular edema
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None